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INTRODUCTION:  Perforation  of intramural  metastasis  to the  stomach  (IMS)  from  esophageal  cancer  during
chemotherapy  has not  been  reported.
PRESENTATION  OF  CASE:  A  68-year-old  male  consulted  our  hospital  due  to appetite  loss.  He  was  diagnosed
with advanced  esophageal  squamous  cell  carcinoma  in  the lower  thoracic  esophagus  along  with  a  large
IMS in the upper  stomach.  The  patient  received  preoperative  chemotherapy  of docetaxel,  cisplatin,  and
5-ﬂuorouracil  (DCF).  During  the second  cycle  of  DCF,  he  had  upper  abdominal  pain  and  was  diagnosed
with  gastric  perforation.  Omental  implantation  repair  for the  perforation,  peritoneal  drainage,  tube-
gastrostomy,  and tube-jejunostomy  were  performed.
At  24  days  after  emergency  surgery,  he  underwent  thoracoscopic  radical  esophagectomy  with  total
gastrectomy  and  reconstruction  with  colonic  interposition.  Pathological  ﬁndings  in the esophagus
demonstrated  complete  replacement  of  the  tumor  by ﬁbrosis.  The  gastric  tumor  was  replaced  by  scar
tissue  with  multinucleated  giant  cells along  with  a small  amount  of  viable  cancer  cells.  The  patient  was
alive  and  healthy  at 14 months  after  the  radical  operation,  without  tumor  recurrence.
DISCUSSION:  The  gastric  perforation  occurred  due  to rapid  regression  of the  IMS  which  had  involved
the  whole  gastric  wall  before  chemotherapy.  Close  monitoring  to  detect  rapid  tumor  shrinkage  during
chemotherapy  in  patients  with  IMS may  be  warranted.  A two-step  operation  was  proposed  to  achieve
safe  curative  treatment  in  patients  with  perforation  of IMS  during  preoperative  chemotherapy.
CONCLUSION:  We  describe  the  ﬁrst reported  case  of  a patient  with  esophageal  squamous  cell  carcinoma
who  showed  perforation  of IMS  during  preoperative  chemotherapy.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Intramural metastasis to the stomach (IMS) from esophageal
ancer is rare [1,2], but is considered to be one of the most impor-
ant poor-prognosis factors associated with a higher risk of distant
etastasis [3].
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Gastro-intestinal perforations during chemotherapy can be
caused by rapid tumor shrinkage and necrosis due to chemotherapy
[4]. The incidence and high mortality rate associated with surgery
for patients with perforation of gastric cancer or gastric lymphoma
during chemotherapy have been reported [4,5]; however, no article
could be found that described perforation of IMS from esophageal
cancer.
Here, we  report a case of esophageal squamous cell carci-
noma (ESCC) which showed perforation of IMS  during preoperative
chemotherapy.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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. Case report
A 68-year-old male consulted one of our hospitals due to
ppetite loss in May  2014. An upper gastrointestinal (GI) endoscopy
evealed an advanced tumor in the lower thoracic esophagus
Fig. 1A) along with a submucosal tumor-like lesion in the upper
tomach (Fig. 1B). Endoscopic biopsy from both tumors revealed
oderately differentiated squamous cell carcinoma (Fig. 1C). Com-
uted tomography (CT) showed high-density tumors in the lower
horacic esophagus (Fig. 1D) and upper stomach (Fig. 1E), but no
vidence of lymph node involvement. The disease was diagnosed
s ESCC with IMS, T3N0M1b Stage IVB, according to the classiﬁca-
ion of the Union for International Cancer Control (UICC, version
).
The patient received preoperative chemotherapy of docetaxel,
isplatin, and 5-ﬂuorouracil (DCF), which consisted of i.v. docetaxel
70 mg/m2) and cisplatin (70 mg/m2) on day 1, and the continuous
nfusion of ﬂuorouracil (750 mg/m2/day) on days 1–5 [6]. The reg-
men was planned to be repeated every 3 weeks with a maximum
f three cycles. The patient showed the nadir of immunosuppres-
ion on day 10 with febrile neutropenia (neutrophils:450/mm3)
nd recovered by treatment with granulocyte-colony stimulating
actor and antibiotics.
On day 5 of the second cycle of DCF, the patient had sudden
pper abdominal pain. CT demonstrated tumor regression in the
ower esophagus (Fig. 2A). Free air and limited ascites were seen
round the regressed tumor in the upper part of the stomach
Fig. 2B).
He was diagnosed with acute panperitonitis due to gastric perfo-
ation and received emergency surgery. Surgical ﬁndings revealed a
-mm perforation at the centre of the induration in the upper part of
he anterior wall of the stomach (Fig. 2C). There was no tumor mass
n the gastric wall. Peritoneal lavage, peritoneal drainage, omental
mplantation repair for the perforation, tube gastrostomy for gas-
ric drainage and tube jejunostomy for feeding were performed.
he patient recovered from surgery without any complications.
ig. 1. (a) Upper gastrointestinal endoscopy showed an advanced tumor in the lower thor
ike  lesion in the upper stomach. (c) Endoscopic biopsy from both tumors revealed mode
n  the lower thoracic esophagus. (e) CT showed high-density tumors in the upper stomacPEN  ACCESS
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At 24 days after the emergency surgery, he underwent thoraco-
scopic radical esophagectomy with total gastrectomy, followed by
reconstruction with colonic interposition. The patient again recov-
ered from surgery without complications.
The gross appearance of the resected specimen revealed tumor
regression both in the lower esophagus and stomach (Fig. 3). Patho-
logical ﬁndings in the lesion of the lower esophagus demonstrated
complete re-epithelialization and the replacement of submucosa
and muscularis propria by ﬁbrosis (Fig. 4A). Multinucleated giant
cells that had phagocytosed corniﬁed substances were observed
scattered throughout the muscularis propria, indicating that squa-
mous cell carcinoma which had involved the deep part of the
muscularis propria had completely regressed with chemotherapy
(Fig. 4A). Pathological ﬁndings in the perforated ulcer scar in the
stomach demonstrated that the gastric wall had been replaced by
scar tissue containing multinucleated giant cells, indicating the
involvement of squamous carcinoma in all layers of the gastric wall
before chemotherapy (Fig. 4B). Although a small number of viable
cancer cells were seen at the horizontal margin of the scar, there
was no evidence of the residual tumor.
No metastasis was observed in any of the dissected mediastinal
or abdominal lymph nodes. Peritoneal lavage cytology showed no
malignant cells. The patient has been closely observed as an out-
patient and was alive and healthy at 14 months after the radical
operation, without any evidence of tumor recurrence.
3. Discussion
IMS  from esophageal cancer is rare with an incidence of 1–1.7%
in surgically resected cases [1,2], but the incidence increases up
to 15% in autopsy cases [7]. The predominant location of the pri-
mary esophageal carcinomas and IMS  have been reported to be
the middle/lower thoracic esophagus and gastric body close to the
esophagocardial junction, respectively [1]. Histologically, the inci-
dence of moderately differentiated squamous cell carcinoma has
acic esophagus. (b) Upper gastrointestinal endoscopy showed a submucosal tumor-
rately differentiated squamous cell carcinoma. (d) CT showed high-density tumors
h.
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eig. 2. (a) CT demonstrated tumor regression in the lower esophagus on day 5 of the
umor  in the upper part of the stomach. (c) Surgical ﬁndings showed perforation in
een reported to be the highest [1], with all ﬁndings consistent
ith our present case.
Microlymphatics in the esophageal submucosa which are con-
inuous with those of the gastric submucosa are considered to play
 key role in IMS  [8].
The prognosis for esophageal cancer patients with IMS  has
een reported to be poor, with an 11.9% postoperative 5-year sur-
ival rate due to a higher rate of distant metastasis [3]. Therefore,
MS  from esophageal cancer is categorized as a distant metastasis
escribed as M1b  Stage IVB, according to the UICC Classiﬁcation.
On the other hand, recent progress in preoperative chemother-
py has facilitated an improved postoperative prognosis even in
dvanced esophageal cancer patients. Based on the results of a
apan Clinical Oncology Study Group trial (JCOG 9907), preop-
rative chemotherapy with cisplatin and 5-ﬂuorouracil (CF) is
egarded as a standard treatment for Stage II/III ESCC in Japan
9]. To further improve survival, a phase II trial demonstrated the
easibility of preoperative DCF for Stage II/III ESCC with an over-
ll response rate of 64.3% [6]. DCF also led to improvement in
oth rapid tumor shrinkage and the survival beneﬁt [6]. Accord-
ngly, a randomized controlled trial comparing CF versus DCF
ersus chemoradiation as neoadjuvant therapy for locally advanced
sophageal cancer is in progress [10]. In addition, preoperative DCF
as also reported to be effective in patients with Stage IV (M1-ymph) disease of esophageal cancer [11]. Based on this reported
vidence, the present case with IMS  received preoperative DCF.
Fig. 3. The gross appearance of the resected specimen revealed tud cycle of DCF. (b) CT demonstrated free air and limited ascites around the regressed
pper part of the stomach.
Oncological gastrointestinal perforation has several causes,
such as spontaneous tumor rupture with rapid tumor progres-
sion, mucosal epithelial cytotoxicity of the anticancer agents or
corticosteroids, and rapid tumor shrinkage or necrosis due to
chemotherapy [6,7,12]. In the present case, the pathological ﬁnd-
ings of the perforated stomach demonstrated total replacement of
the gastric wall by ﬁbrosis containing multinucleated giant cells
which phagocytosed squamous cell carcinoma, indicating that the
perforation occurred due to rapid regression of the IMS  which had
involved in the whole gastric wall before chemotherapy.
In the present case, we  started the second cycle of DCF without
imaging diagnosis to assess the response to the ﬁrst cycle. A close
observation using CT or upper GI endoscopy is proposed before
starting the next cycle of chemotherapy, not only to rule out the
progression of the tumor due to a poor therapeutic response, but
also to rule out too rapid tumor regression of large IMS.
The mortality rate following surgery for perforated gastric can-
cer during chemotherapy was reported to be 40 to 80%, because
of immunosuppression and/or undernutrition [6]. In the present
case, considering that the nadir of neutropenia was predicted at 5
days after perforation, we  performed a two-step operation. Firstly,
we performed repair of the perforation, peritoneal drainage, gas-
tric drainage, and tube jejunostomy for feeding to support recovery
with minimal surgical invasion. Then, we could safely perform a
radical resection after the recovery of the general status without
any perioperative complications.
mor regression in both the lower esophagus and stomach.
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Fig. 4. (a) Pathological ﬁndings in the lesion of the lower esophagus demonstrated complete re-epithelialization, and replacement of the submucosa and muscularis propria
by  ﬁbrosis. Multinucleated giant cells that had phagocytosed corniﬁed substances were observed scattered throughout the muscularis propria. (b) Pathological ﬁndings in
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of this journal on request.he  perforated ulcer scar in the stomach demonstrated that the gastric wall had bee
ancer  cells were seen at the horizontal margin of the scar.
. Conclusions
Here, we describe, to our knowledge, the ﬁrst reported case of
 patient with esophageal squamous cell carcinoma who  showed
erforation of IMS  during chemotherapy. Close monitoring to
etect rapid tumor shrinkage during chemotherapy in patients
ith large IMS  may  be warranted. A two-step operation was pro-
osed to achieve curative treatment with safety and minimal
urgical invasion in a patient with perforation of IMS  during pre-
perative chemotherapy.
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